Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules.
Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment in Metastatic Urothelial Cancer: A Randomized Phase II Study of Two Alternative Dosing Schedules. Clin Genitourin Cancer. 2026 Aug; 24(5):102577.
PMID: 42217273
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial.
Pembrolizumab in Combination With Gemcitabine and Concurrent Hypofractionated Radiation Therapy as Bladder-sparing Treatment for Muscle-invasive Urothelial Cancer of the Bladder: A Multicenter Phase 2 Trial. Eur Urol. 2026 Apr 06.
PMID: 41945031
Evaluating Perceived Value of Pharmacogenomic Testing After a Personalized Therapeutics Clinic Consultation.
Evaluating Perceived Value of Pharmacogenomic Testing After a Personalized Therapeutics Clinic Consultation. Clin Transl Sci. 2026 04; 19(4):e70537.
PMID: 41949895
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer.
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer. N Engl J Med. 2026 Apr 02; 394(13):1257-1269.
PMID: 41707170
Dear Doctor: We Still Have No Idea of What Dose of Capecitabine You Should Prescribe.
Dear Doctor: We Still Have No Idea of What Dose of Capecitabine You Should Prescribe. J Clin Oncol. 2026 May; 44(13):1186-1189.
PMID: 41610386
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists.
Preferred Treatment Sequencing for Metastatic Urothelial Carcinoma (mUC) in the Era of Perioperative and First-Line (1L) Checkpoint Inhibitor: Results From a National Survey of Genitourinary Oncologists. Clin Genitourin Cancer. 2026 Mar; 24(2):102487.
PMID: 41582039
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer.
Association of SULT2A1 Locus With Abiraterone Clearance in the Alliance A031201: Randomized Phase III Study of Enzalutamide Compared With Enzalutamide Plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer. Clin Transl Sci. 2025 12; 18(12):e70425.
PMID: 41346252
Results of the ACCOuNT Trial: A Multi-Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients.
Results of the ACCOuNT Trial: A Multi-Institutional Prospective Pharmacogenomics Implementation Trial for African American Inpatients. Clin Pharmacol Ther. 2026 01; 119(1):109-119.
PMID: 40847467
HER2 and urothelial carcinoma: current understanding and future directions.
HER2 and urothelial carcinoma: current understanding and future directions. Nat Rev Urol. 2026 02; 23(2):110-132.
PMID: 40817396
Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes.
Impact of First-of-Its-Kind Patient-Facing Pharmacogenetics Tool on Dosing Decisions and Treatment Outcomes. Clin Pharmacol Ther. 2025 10; 118(4):906-916.
PMID: 40579854